

FY22 Results Presentation

2 March 2023



Disclaimer

These materials contain certain forward-looking statements relating to the business of Spire Healthcare Group plc (the "Company"), including with respect to the progress, timing and completion of the Company's development, the Company's ability to treat, attract, and retain patients and customers, its ability to engage consultants and GPs and to operate its business and increase referrals, the integration of prior acquisitions, the Company's estimates for future performance and its estimates regarding anticipated operating results, future revenues, capital requirements, shareholder structure and financing. In addition, even if the Company's actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Company's results or developments in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "aims," "targets," "anticipates," "believes," "intends," "estimates," or similar words. These forward-looking statements are based largely on the Company's current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the Company's expectations could be affected by, among other things, uncertainties involved in the integration of acquisitions or new developments, changes in legislation or the regulatory regime governing healthcare in the UK, poor performance by consultants who practice at our facilities, unexpected regulatory actions or suspensions, competition in general, the impact of global economic changes, and the Company's ability to obtain or maintain accreditation or approval for its facilities or service lines. In light of these risks and uncertai

The Company is providing the information in these materials as of this date, and we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





Zoom webinar rules of engagement

All attendee lines are muted

The chat function is disabled

Please submit your name and organisation using the Q&A function

Angus will moderate the session and unmute your line for you to ask your question

Any problems please email Laura. Young@spirehealthcare.com





Agenda

FY22 Overview

Justin Ash, Chief Executive Officer

FY22 Financial review

Jitesh Sodha, Chief Financial Officer

Strategic developmentsJustin Ash, Chief Executive Officer

Expanding our propositionPeter Corfield, Chief Commercial Officer

Outlook for FY23

Justin Ash, Chief Executive Officer

Q&A







FY22 Overview

Justin Ash, Chief Executive Officer

Our purpose: Making a positive difference to people's lives through outstanding personalised care

Our strategy

Help to meet UK healthcare needs by running great hospitals and developing new services



Drive hospital performance

Continue growth in our existing hospital estate with increasing margins



Build on quality

Maintain strong
quality and safety
credentials as a
competitive
advantage in all our
activities



Invest in our workforce

Recruit, retain and develop a great workforce



Champion sustainability

Become recognised as an ESG leader in our industry



Expand our proposition

Selectively invest to attract patients and meet more of their healthcare needs



Deliver strong financial performance


Financial discipline supporting cash generation, targeted investment and improving ROCE / shareholder returns






FY22 – a period of good progress








>£15m cost savings delivered as planned

> On track to deliver further £15m cost savings in 2023-24



Proposed final dividend of 0.5 pence per share – in line with dividend policy





Continued strong demand

Market: Continued demand against backdrop of strain in the NHS

Self-pay

Demand materially higher than prepandemic

PMI

Recovered well

NHS

Focus on eRS referrals and orthopaedics






Managing in a challenging environment

Focus on margins through COVID-19 disruption, high inflation and workforce pressure

Sickness amongst colleagues 5.5% (2% pre-pandemic)

COVID-19 impact £42.9m

(FY21:£53m)



Adjusted EBITDA margin
17.0%
(FY21: 16.1%)





Delivering on our purpose

98% of inspected sites 'Good',
'Outstanding' by the CQC (or equivalent in
Scotland and Wales)

96% patients rating experience as 'Good' or 'Very Good'

86% agree that our care has made a positive difference (no change)

92% agree that our care was outstanding (no change)

94% agree that our care was personalised (no change)

Source: Spire Healthcare Patient Discharge Survey
Base: 2022, Positive Difference n=40,740; Base: 2022, Outstanding / Personalised Care n=44,750
Notes: Scores shown are based on full year 2022 data, change measured versus 2021. 'Positive Difference' excludes 'Too early to tell'





Thank you to our people







FY22 Financial Review

Jitesh Sodha, Chief Financial Officer

Financial headlines FY22: P&L

Revenue **£1,198.5m**

(FY21: £1,106.2m)

Adjusted EBITDA **£203.5m**

(FY21: £178.2m)

Adjusted EBIT **£105.6m**

(FY21: £81.1m)

Adjusted
Profit Before
Tax
£14.1m

(FY21: Loss £7.0m)

ROCE **6.2%**

(FY21: 4.9%)

Adjusted EBITDA Margin 17.0%

(FY21: 16.1%)

Adjusted EBIT
Margin
8.8%

(FY21: 7.3%)

Statutory
Profit After
Tax
£8.2m

(FY21: Loss £8.9m)





Financial headlines FY22: balance sheet

Capex **£90.1m**

(FY21: £77.1m)

Net bank debt £250.1m

(FY21: £224.9m)

ratio (Net Debt/EBITDA)

2.2x

(FY21: 2.3x)


Repaid £100m of bank loan

Re-financed £325m senior facility

Acquired The Doctors Clinic Group for £12m




Payor mix: maintained focus on Private






(2020 & Q1 2021 impact by NHS COVID-19 contracts)


Private revenue growth






Private volumes – outpatient and procedures









Self-pay – Admissions and ARPC









PMI – Admissions and ARPC









NHS – Admissions and ARPC








Margin improvement





EBITDA Covenant Leverage



IFRS 16 results in future lease rentals being recognised as Debt (EBITDA to total debt ratio decreased to 5.5x from 5.9x).

Fair Value of Freehold Portfolio >£1.3bn but held on balance sheet at £652.2m

Loan to value ratio less than 1





Capex and portfolio management

Targeted Capex

- Focused on payback and ROCE
- 6-7% of revenue on average to fund core estate and capacity projects (average 6.7% 2020-22)
- Major capacity projects funded within existing Capex

• Yale: £11m

• Edinburgh Shawfair: £8m

Portfolio management

Sold Sussex and acquired Claremont

• Improvement in ROCE of 20%

Genesis profit share arrangement:

• Return over 10% ahead of plan

The Doctors Clinic Group

Spire Yale









Strategic developments

Justin Ash, Chief Executive Officer

Our purpose: Making a positive difference to people's lives through outstanding personalised care

Our strategy

Help to meet UK healthcare needs by running great hospitals and developing new services



Drive hospital performance

Continue growth in our existing hospital estate with increasing margins



Build on quality

Maintain strong
quality and safety
credentials as a
competitive
advantage in all our
activities



Invest in our workforce

Recruit, retain and develop a great workforce



Champion sustainability

Become recognised as an ESG leader in our industry



Expand our proposition

Selectively invest to attract patients and meet more of their healthcare needs



Deliver strong financial performance

Financial discipline supporting cash generation, targeted investment and improving ROCE / shareholder returns






Pillar: Drive hospital performance



Hip and knee procedures

Volume among independent sector providers



Source: Spire Healthcare analysis of NJR data



Pillar: Build on quality



Delivered Quality
Improvement
initiatives

98% of inspected sites 'Good', 'Outstanding' by the CQC (or equivalent in Scotland and Wales)

3rd year of only 'Good' or 'Outstanding' ratings





Pillar: Invest in our workforce



- 5% pay award to colleagues in September; lower paid up to 16% over the year
- Around 1,000 colleagues on a development programme
- 5% of permanent workforce participating in one of our apprenticeships
- Bringing recruitment in-house

- 80% of colleagues proud to work for Spire Healthcare
- 78% of consultants rate the quality of care given to their patients by Spire Healthcare as 'Excellent' or 'Very Good'





Pillar: Champion sustainability



- On track to becoming net carbon zero by 2030
- Reduced carbon emissions in 2022 by 6%

- Initiatives include:
 - Replacing gas-power boilers
 - Installing electric vehicle charging points
 - Increasing recycling rates
 - Reducing waste sent to landfill

 Highly commended for 'Net Zero Strategy of the Year' at BusinessGreen Leaders Awards





Pillar: Expand our proposition



- Investing to attract patients and meet more of their healthcare needs
- Working to becoming an integrated healthcare provider
- Services in:
 - Primary care
 - Diagnosis
 - Occupational health
 - Long-term condition management
- Purchased The Doctors Clinic Group







Expanding our proposition

Peter Corfield, Chief Commercial Officer

Our three areas of focus to expand our proposition

Spire Healthcare new services

Day case clinics

- Standalone day case facilities
- One stop clinic for key specialities
- Includes diagnostics
- 1 or 2 theatres (local anaesthetic)

2 Spire Clinics to be launched in 2023

Primary healthcare

- Private GP services
- Minor procedures
- Health assessments
- Chronic condition management

Available in 56 locations (35 in hospitals; 21 standalone)

Occupational health

- Industrial health compliance
- Back to work support
- Employee health assessments and screening

700 corporate clients





The Doctors Clinic Group



- Modest investment in company with 200 employees
- Platform for growth and synergies with existing business
- Aligned to Spire Healthcare's five-year growth strategy
 - Meeting increased demand for healthcare in the UK
 - Supporting delivery of a broader range of healthcare services
- Provides entry into a new market occupational health
- Broadening our reach into the London market





The Doctors Clinic Group cont'd

Occupational health

- Over 700 clients
- Full range of health and wellbeing services
- Growing market as employers looks to improve attendance, retention and attraction
- Opportunity for downstream referrals
- OH market highly fragmented



- Re-brand service to Spire Healthcare
- Diagnostic and secondary care referral pathways
- Organic growth and synergies
- Develop proposition (eg InSpire)

Primary healthcare

- 22 medical centres, 8 in central London
- Private GP market growing
- Opportunity for downstream referrals
- Integration and scale-up opportunity
- Defined strategy for geographic expansion



- Re-brand service to Spire Healthcare
- Diagnostic and secondary care referral pathways
- Increase number of medical centres
- Synergies (eg medical drugs)







Outlook

Justin Ash, Chief Executive Officer

Outlook for 2023

Anticipate further growth in revenue, profit and ROCE

Private revenue growth; modest increase in NHS activity

Further margin improvement

Sustained pressures in workforce especially people costs and absence, and healthcare inflation

Ongoing savings programme and pricing management – impact mainly in H2

Committed to highest quality patient care and increasing sustainability







FY22 Results Presentation

2 March 2023





Appendix

Technical guidance


Technical guidance for 2023					
Total property rent	c.£92-97m (FY22: £93.7m)				
D&A	c.£100-105m (FY22: £97.9m)				
Capex*	c.£80-90m (FY22: £90.1m)				
Net financing costs	c.£93-100m (FY22: £94.6m)				
Tax**	Effective corporate tax rate between 30-40% as a result of deferred tax movements (FY22: NM)				
Net bank debt	c.£200-250m (31 December 2022: £250.1m)				

^{**} The tax effective rate is driven by the statutory rate of 25%, adjusted for disallowable items (eg non-qualifying depreciation) and movements on deferred tax (primarily in respect of IFRS 16 leases)



^{*} Excludes Capex on clinics or adjacent propositions

Private volumes – outpatient and admissions




Private IPDC admissions







Revenue by Payor





Cost of sales analysis





Maintained higher ARPC – reflects pricing, private mix and acuity

	PMI			Self-pay			Total private		
	FY19	FY21	FY22	FY19	FY21	FY22	FY19	FY21	FY22
IPDC admissions ('000s)	121.6	104.9	118.2	47.6	63.7	69.5	169.3	168.6	187.7
ARPC (£)	2,533	2,686	2,756	2,884	3,683	3,955	2,632	3,062	3,199
ARPC YOY growth (%)			+2.6			+7.4			+4.5
Total revenue (£m)	491.8	473.7	538.7	178.8	292.0	338.0	670.6	765.7	876.7

	NHS							
FY19	FY21	FY22						
92.0	75.0	75.1						
2,434	2,731	3,129						
		+14.6						
285.7	314.5	295.4						



Note: NHS ARPC is stated gross of consultant fees

Cash flow

£m	FY22	FY21	FY20	FY19
Cash from operating activities	196.7	172.4	160.0	184.9
Working capital movement	(15.0)	11.4	(3.9)	17.9
Capex	(87.7)	(67.0)	(46.3)	(60.2)
Proceeds from disposal of assets *	3.7	88.9	-	11.6
Acquisition cash outflow **	(11.3)	(14.7)	-	-
Financing activities	(214.7)	(94.7)	(97.9)	(110.0)
Tax	(0.1)	-	3.6	(1.1)
(Decrease)/Increase in cash	(128.4)	96.3	15.5	43.1
Opening cash balance	202.6	106.3	90.8	47.7
Closing cash balance	74.2	202.6	106.3	90.8


^{*}Proceeds in 2021 relate to the sale and leaseback of Spire Cheshire and the sale of Spire Sussex. Proceeds in 2019 relates to the sale of Bristol and Baddow Specialist Cancer Centres.

^{**}The costs of acquisitions relates to the Claremont Hospital.





Cash





Cash and borrowings

£m	Dec 22	Dec 21	Dec 20
Bank borrowings	324.3	427.5	420.8
Cash	74.2	202.6	106.3
Net bank debt	250.1	224.9	314.5
£m	Dec 22	Dec 21	Dec 20
£m Bank borrowings	Dec 22 324.3	Dec 21 427.5	Dec 20 420.8





Net bank debt and Total debt under IFRS16


Net Bank Debt	2022 YE £m	2021 YE £m
Bank Debt (incl. paid fees and accrued interest)	324.3	427.5
less Cash	74.2	202.6
Net Bank Debt	250.1	224.9

Total Debt (IFRS 16)	2022 YE £m	2021 YE £m
Bank Debt (incl. paid fees and accrued interest)	324.3	427.5
Plus Lease Liabilities	866.5	837.8
Total IFRS 16 Debt	1,190.8	1,265.3
Less Cash	74.2	202.6
Net Total IFRS 16 Debt	1,116.6	1,062.7
EBITDA/ Net Total Debt Ratio	5.5	5.9






Continued exposure to COVID impact – last 12 months





Latest NHS England waiting list



Source: NHS England: https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/






Comfort on current income: UK adults and our target population

We asked how they felt about their current financial situation



- Finding it difficult on present income
- Coping on present income
- Comfortable on present income
- Very comfortable on present income




Q. Which one of the following best describes how you feel about your financial situation at the moment?






Ease of accessing £5k: UK adults and our target population

- We asked how easily they could find £5,000 for medical treatment if they needed to
- Target population: Still more resilient than the population at large





Q. How easily could you access £5,000 for medical treatment if you felt you really needed to?





Hospital and clinic ratings from CQC, HIW* and HIS[†]

Site	Rating	Site	Rating	Site	Rating	Site	Rating
Alexandra ¹	Requires Improvement	Edinburgh/Shawfair [†]	Good	London East	Good	Thames Valley	Good
Brighton/Montefiore	Outstanding	Elland	Good	Manchester	Outstanding	Tunbridge Wells	Good
Bristol	Good	Fylde Coast	Good	Methley Park	Good	Washington	Good
Bushey	Good	Gatwick	Good	Norwich	Good	Wellesley	Good
Cambridge Lea	Good	Harpenden	Good	Nottingham	Outstanding	Wirral	Good
Cardiff*	Positive	Hartswood	Good	Parkway	Good	Yale*	Positive
Cheshire	Outstanding	Hull	Good	Portsmouth	Good		
Clare Park	Good	Leeds	Good	Regency	Good		
Claremont	Outstanding	Leicester	Good	South Bank	Good		
Dunedin	Good	Little Aston	Good	Southampton	Good		
Edinburgh/Murrayfield [†]	Exceptional	Liverpool	Good	St. Anthony's	Good		
Abergele Clinic*	Positive	Hesslewood Clinic	Good	London Bridge	Good	Waterloo	Good
Bushey Diagnostic Centre	Good	Kings Cross	Good	Old Street	Good		



¹ Last inspected in 2016



^{*} Healthcare Inspectorate Wales

[†] Healthcare Improvement Scotland